These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 18339875)

  • 1. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
    Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
    Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
    Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
    Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
    Shi Q; Hjelmeland AB; Keir ST; Song L; Wickman S; Jackson D; Ohmori O; Bigner DD; Friedman HS; Rich JN
    Mol Carcinog; 2007 Jun; 46(6):488-96. PubMed ID: 17219439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR.
    Golubovskaya VM; Virnig C; Cance WG
    Mol Carcinog; 2008 Mar; 47(3):222-34. PubMed ID: 17849451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.
    Watanabe N; Takaoka M; Sakurama K; Tomono Y; Hatakeyama S; Ohmori O; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Beer DG; Nagatsuka H; Tanaka N; Naomoto Y
    Clin Cancer Res; 2008 Jul; 14(14):4631-9. PubMed ID: 18628478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models.
    Golas JM; Lucas J; Etienne C; Golas J; Discafani C; Sridharan L; Boghaert E; Arndt K; Ye F; Boschelli DH; Li F; Titsch C; Huselton C; Chaudhary I; Boschelli F
    Cancer Res; 2005 Jun; 65(12):5358-64. PubMed ID: 15958584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma.
    Medicherla S; Reddy M; Ying J; Navas TA; Li L; Nguyen AN; Kerr I; Hanjarappa N; Protter AA; Higgins LS
    Anticancer Res; 2008; 28(6A):3827-33. PubMed ID: 19189670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.
    Rhodes N; Heerding DA; Duckett DR; Eberwein DJ; Knick VB; Lansing TJ; McConnell RT; Gilmer TM; Zhang SY; Robell K; Kahana JA; Geske RS; Kleymenova EV; Choudhry AE; Lai Z; Leber JD; Minthorn EA; Strum SL; Wood ER; Huang PS; Copeland RA; Kumar R
    Cancer Res; 2008 Apr; 68(7):2366-74. PubMed ID: 18381444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.
    Stokes JB; Adair SJ; Slack-Davis JK; Walters DM; Tilghman RW; Hershey ED; Lowrey B; Thomas KS; Bouton AH; Hwang RF; Stelow EB; Parsons JT; Bauer TW
    Mol Cancer Ther; 2011 Nov; 10(11):2135-45. PubMed ID: 21903606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.
    Liu FJ; Gui SB; Li CZ; Sun ZL; Zhang YZ
    Chin Med J (Engl); 2008 Sep; 121(17):1702-6. PubMed ID: 19024103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors: implications for bone metastases.
    Bagi CM; Roberts GW; Andresen CJ
    Cancer; 2008 May; 112(10):2313-21. PubMed ID: 18348298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors.
    Mitra SK; Mikolon D; Molina JE; Hsia DA; Hanson DA; Chi A; Lim ST; Bernard-Trifilo JA; Ilic D; Stupack DG; Cheresh DA; Schlaepfer DD
    Oncogene; 2006 Sep; 25(44):5969-84. PubMed ID: 16682956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FAK expression regulation and therapeutic potential.
    Li S; Hua ZC
    Adv Cancer Res; 2008; 101():45-61. PubMed ID: 19055942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of small molecule inhibitors of proline-rich tyrosine kinase 2 (Pyk2) with osteogenic activity in osteoblast cells.
    Allen JG; Lee MR; Han CY; Scherrer J; Flynn S; Boucher C; Zhao H; O'Connor AB; Roveto P; Bauer D; Graceffa R; Richards WG; Babij P
    Bioorg Med Chem Lett; 2009 Sep; 19(17):4924-8. PubMed ID: 19648005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase.
    Hu XW; Meng D; Fang J
    Carcinogenesis; 2008 Dec; 29(12):2369-76. PubMed ID: 18974065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells.
    Weng JR; Tsai CH; Kulp SK; Wang D; Lin CH; Yang HC; Ma Y; Sargeant A; Chiu CF; Tsai MH; Chen CS
    Cancer Res; 2007 Aug; 67(16):7815-24. PubMed ID: 17699787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.